Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Cancer Therapy Market: By Therapy Type, By Cancer Type, By End User, and Region Forecast 2019-2030
Cancer Therapy Market: By Therapy Type, By Cancer Type, By End User, and Region Forecast 2019-2030
The global cancer therapy market size was valued at US$ 158.4 billion in 2023 and is projected to reach at US$ 310.6 billion by 2030, at a CAGR of 10.1% from 2024-2030. Cancer therapy refers to the various treatments used to combat cancer, a group of diseases characterized by uncontrolled growth and spread of abnormal cells. There are several types of cancer therapies, each designed to target cancer cells in different ways. The choice of therapy depends on the type of cancer, its stage, the patient’s overall health, and other factors.
The key market drivers of cancer therapy market are global rise in cancer cases, increase in product launches/approval for cancer therapies. However, the restraints of cancer therapy market which are hampering the growth of market are cancer drug resistance and cancer heterogeneity for instance, two patients with the same type of breast cancer may have different genetic mutations resulting in different responses to treatment along with different drugs, high treatment costs, side effects & toxicity due to cancer treatments. The emerging opportunities of cancer therapy market are rising demand for precision medicine, growing focus on early detection and preventive care and growth of biosimilars. The key trends of cancer therapy market are demand to use AI in drug discovery of cancer and development in novel therapies.
The leading companies highlighted in the cancer therapy market report include such as GlaxoSmithKline focuses on oncology research offering products like Blenrep (belantamab mafodotin), treatment for multiple myeloma ; Eli Lilly & Company is a leader in oncology focusing on treatment of breast, lung, and colorectal cancers ; F. Hoffmann-La Roche Ltd offers Herceptin (trastuzumab), Avastin (bevacizumab), Tecentriq (atezolizumab) ; AbbVie Inc., specializes in hematologic oncology with a focus on targeted cancer therapies ; Merck & Co., Inc is a leader in immuno-oncology and is known for its checkpoint inhibitors and others are Novartis AG, Pfizer Inc, AstraZeneca, Elekta AB, Amgen Inc. Also, a comprehensive analysis of industry verticals and market participants that provides a clear overview of the competitive landscape in relation to the sectors served by the company’s products and services, market share, service offerings, financial reports, significant developments, market strategy, competitive position, and geographic reach.
By Therapy: Among all therapy types, chemotherapy and radiotherapy is dominating the cancer therapy market due to their treatment efficacy, and broad applicability as chemotherapy and radiotherapy can be used to treat various types of cancer, including those that are difficult to target with other therapies, and also compared to newer, more advanced therapies, chemotherapy and radiotherapy are more cost-effective, making them a preferred choice in many healthcare systems.
By Cancer: Among the above-mentioned cancer types, breast cancer accounts the highest percentage in cancer therapy market due lifestyle changes, hormonal imbalances, genetic predisposition, and aging population contribute to the rising number of breast cancer cases. In 2024, an estimated 310,720 new cases of invasive breast cancer will be diagnosed in women.
By End-user: Among all the end users, hospitals are the most widely used in the cancer therapy market. As, hospitals typically have the comprehensive infrastructure, multidisciplinary teams, and advanced technologies required to provide a wide range of cancer treatments, including surgery, chemotherapy, radiation therapy, and supportive care. Hospitals are often the primary point of care for cancer patients, offering both initial diagnosis and ongoing treatment.
Study Period
2024-2030Base Year
2023CAGR
10.1%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Rise in cancer cases is one of the significant driver of cancer therapy market. For example, in 2022, there were almost 20 million new cancer cases and 9.7 million cancer-related deaths worldwide. The rising use of combination therapies is a key driver of the cancer therapy market as it enhances treatment efficacy and reduces resistance by combining different therapeutic agents and modalities and combination therapies target multiple pathways simultaneously exploiting synergistic effects that can lead to better outcomes. This approach is particularly effective in overcoming the limitations of single-agent therapies and addressing the complexity of cancer biology as a result, the demand for combination therapies is increasing contributing to the growth of the cancer therapy market.
Cancer drug resistance is one of the restraint on the cancer therapy market as it limits the effectiveness of treatments and leads to poorer patient outcomes. When cancer cells develop resistance to drugs, they become less responsive to treatment, making it harder to control or eliminate the disease which can result in the need for higher doses of drugs, combination therapies, or new treatment strategies, all of which can increase healthcare costs and patient irritation.
The growing focus on early detection and preventive care presents a significant opportunity for the cancer therapy market as it can lead to better patient outcomes and reduced treatment costs. Early detection of cancer increases the chances of successful treatment, as cancers caught in their initial stages are often more manageable and less aggressive. Preventive care, including lifestyle modifications and vaccinations, can reduce the incidence of certain cancers. Together, these approaches can decrease the overall burden of cancer, leading to increased demand for early detection technologies, screening programs, and preventive measures, thereby driving market growth.
The demand to use AI in drug discovery and the development of novel therapies is a significant trend in the cancer therapy market due to several reasons like accelerated drug discovery, AI-driven platforms which can analyse patient data to develop personalized treatment plans improving the efficacy of cancer therapies and adopting predictive analytics in which AI can predict how different drugs will interact with various cancer types helping researchers design more effective combination therapies.
North America in cancer therapy market is expected to dominate due to factors like increase prevalence of cancer, high investment in oncology R&D in this region. Along with that in the United States, the rate of new cancer cases was 440.5 per 100,000 people per year between 2017 and 2021. However, Asia Pacific region in cancer therapy market is expected to exhibit a rapid growth rate due to advancements in treatment, development in healthcare infrastructure with India, China, Japan, and South Korea projected to be the most opportune countries.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 158.4 billion |
|
Market Size in 2030 |
US$ 310.6 billion |
|
Market CAGR |
10.1% |
|
By Therapy Type |
|
|
By Cancer Type |
|
|
By End User |
|
|
By Region |
|
The cancer therapy market is experiencing significant growth driven by several key factors. The rising prevalence of cancer worldwide is a major contributor, as more individuals are diagnosed with various types of cancer, necessitating effective treatment options. Additionally, advancements in cancer therapies, including targeted therapies, immunotherapies, and combination treatments, are improving patient outcomes and expanding treatment options. Government initiatives and increased funding for cancer research are also playing a crucial role in the market's growth. These initiatives are aimed at raising cancer awareness, improving screening programs, and providing better access to advanced treatments. Furthermore, the growing focus on personalized medicine and the development of novel therapies tailored to individual patients' needs are driving innovation in the field of cancer therapy market.
Download Free Sample Report
The global cancer therapy market is projected to expand from US$ 158.4 billion in 2023 to US$ 310.6 billion by 2030, at a CAGR of 10.1% from 2024-2030.
• Global rise in cancer cases
• Increase in product launches/approval for cancer therapies.
The key market players of GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc .
North America region is dominating the cancer therapy market.
| 1.Executive Summary |
| 2.Global Cancer Therapy Market Introduction |
| 2.1.Global Cancer Therapy Market - Taxonomy |
| 2.2.Global Cancer Therapy Market - Definitions |
| 2.2.1.Therapy Type |
| 2.2.2.Cancer Type |
| 2.2.3.End-user |
| 2.2.4.Region |
| 3.Global Cancer Therapy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Cancer Therapy Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Cancer Therapy Market By Therapy Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Chemotherapy |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Surgery |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Radiotherapy |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Immunotherapy |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Targeted Therapy |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Hormone Therapy |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Stem Cell Transplant |
| 5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Photodynamic Therapy |
| 5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 5.9. Others |
| 5.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.9.3. Market Opportunity Analysis |
| 6.Global Cancer Therapy Market By Cancer Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Breast |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Colorectal |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Prostate |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Blood |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Liver |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Thyroid |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Skin |
| 6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 6.8. Lung |
| 6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.8.3. Market Opportunity Analysis |
| 6.9. Others |
| 6.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.9.3. Market Opportunity Analysis |
| 7.Global Cancer Therapy Market By End-user, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Speciality Clinics |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Cancer Therapy Centre |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Radiation Therapy Centre |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Others |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.Global Cancer Therapy Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Cancer Therapy Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Therapy Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Chemotherapy |
| 9.1.2.Surgery |
| 9.1.3.Radiotherapy |
| 9.1.4.Immunotherapy |
| 9.1.5.Targeted Therapy |
| 9.1.6.Hormone Therapy |
| 9.1.7.Stem Cell Transplant |
| 9.1.8.Photodynamic Therapy |
| 9.1.9.Others |
| 9.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Breast |
| 9.2.2.Colorectal |
| 9.2.3.Prostate |
| 9.2.4.Blood |
| 9.2.5.Liver |
| 9.2.6.Thyroid |
| 9.2.7.Skin |
| 9.2.8.Lung |
| 9.2.9.Others |
| 9.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals |
| 9.3.2.Speciality Clinics |
| 9.3.3.Cancer Therapy Centre |
| 9.3.4.Radiation Therapy Centre |
| 9.3.5.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Cancer Therapy Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Therapy Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Chemotherapy |
| 10.1.2.Surgery |
| 10.1.3.Radiotherapy |
| 10.1.4.Immunotherapy |
| 10.1.5.Targeted Therapy |
| 10.1.6.Hormone Therapy |
| 10.1.7.Stem Cell Transplant |
| 10.1.8.Photodynamic Therapy |
| 10.1.9.Others |
| 10.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Breast |
| 10.2.2.Colorectal |
| 10.2.3.Prostate |
| 10.2.4.Blood |
| 10.2.5.Liver |
| 10.2.6.Thyroid |
| 10.2.7.Skin |
| 10.2.8.Lung |
| 10.2.9.Others |
| 10.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Speciality Clinics |
| 10.3.3.Cancer Therapy Centre |
| 10.3.4.Radiation Therapy Centre |
| 10.3.5.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Cancer Therapy Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Therapy Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Chemotherapy |
| 11.1.2.Surgery |
| 11.1.3.Radiotherapy |
| 11.1.4.Immunotherapy |
| 11.1.5.Targeted Therapy |
| 11.1.6.Hormone Therapy |
| 11.1.7.Stem Cell Transplant |
| 11.1.8.Photodynamic Therapy |
| 11.1.9.Others |
| 11.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Breast |
| 11.2.2.Colorectal |
| 11.2.3.Prostate |
| 11.2.4.Blood |
| 11.2.5.Liver |
| 11.2.6.Thyroid |
| 11.2.7.Skin |
| 11.2.8.Lung |
| 11.2.9.Others |
| 11.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Speciality Clinics |
| 11.3.3.Cancer Therapy Centre |
| 11.3.4.Radiation Therapy Centre |
| 11.3.5.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Cancer Therapy Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Therapy Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Chemotherapy |
| 12.1.2.Surgery |
| 12.1.3.Radiotherapy |
| 12.1.4.Immunotherapy |
| 12.1.5.Targeted Therapy |
| 12.1.6.Hormone Therapy |
| 12.1.7.Stem Cell Transplant |
| 12.1.8.Photodynamic Therapy |
| 12.1.9.Others |
| 12.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Breast |
| 12.2.2.Colorectal |
| 12.2.3.Prostate |
| 12.2.4.Blood |
| 12.2.5.Liver |
| 12.2.6.Thyroid |
| 12.2.7.Skin |
| 12.2.8.Lung |
| 12.2.9.Others |
| 12.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Speciality Clinics |
| 12.3.3.Cancer Therapy Centre |
| 12.3.4.Radiation Therapy Centre |
| 12.3.5.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Cancer Therapy Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Therapy Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Chemotherapy |
| 13.1.2.Surgery |
| 13.1.3.Radiotherapy |
| 13.1.4.Immunotherapy |
| 13.1.5.Targeted Therapy |
| 13.1.6.Hormone Therapy |
| 13.1.7.Stem Cell Transplant |
| 13.1.8.Photodynamic Therapy |
| 13.1.9.Others |
| 13.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Breast |
| 13.2.2.Colorectal |
| 13.2.3.Prostate |
| 13.2.4.Blood |
| 13.2.5.Liver |
| 13.2.6.Thyroid |
| 13.2.7.Skin |
| 13.2.8.Lung |
| 13.2.9.Others |
| 13.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Speciality Clinics |
| 13.3.3.Cancer Therapy Centre |
| 13.3.4.Radiation Therapy Centre |
| 13.3.5.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Amgen Inc |
| 14.2.2.AbbVie Inc |
| 14.2.3.AstraZeneca |
| 14.2.4.Elekta AB |
| 14.2.5.Eli Lilly & Company |
| 14.2.6.GlaxoSmithKline |
| 14.2.7.Hoffmann-La Roche Ltd |
| 14.2.8.Merck & Co., Inc |
| 14.2.9.Novartis AG |
| 14.2.10.Pfizer Inc |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.